Publications by authors named "Yukio Kobayashi"

Introduction: Cardiac sympathetic denervation is specific to Lewy body disease (LBD). In Parkinson's disease (PD), sympathetic denervation in the major salivary glands (parotid glands [PG] and submandibular glands [SMG]) has been demonstrated by I-metaiodobenzylguanidine (MIBG) scintigraphy. We compared sympathetic denervation in the MSG between PD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP).

View Article and Find Full Text PDF

Deep molecular response (DMR) is a prerequite for treatment-free remission (TFR) in chronic myeloid leukemia in chronic phase (CML-CP). The JALSG (Japan Adult Leukemia Study Group) conducted a prospective randomized phase 3 CML212 study for de novo CML-CP to compare the cumulative achievement of molecular response 4.5 (MR4.

View Article and Find Full Text PDF

Background: Parkinson's disease (PD) shows cardiac sympathetic denervation (SD) in I-metaiodobezylguanidine (MIBG) scintigraphy. Recently, SD in the major salivary glands (MSG-SD) was introduced as a possible radiological feature of PD.

Objective: To identify the clinical characteristics of patients with PD with reduced MSG and cardiac MIBG uptake (dual-SD) compared with those with reduced MSG or cardiac MIBG uptake only (single-SD).

View Article and Find Full Text PDF

Objectives: To analyze I-metaiodobenzylguanidine (MIBG) uptake in the parotid and submandibular glands in patients with Parkinson's disease (PD) in comparison with controls, and to compare MIBG uptake between those glands and the myocardium. Furthermore, we aimed to identify the relationships between clinical features and MIBG uptake.

Methods: We recruited 77 patients with PD and 21 age-matched controls.

View Article and Find Full Text PDF

Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We report findings from a phase 1/1b study in East Asian patients with AML or MDS, conducted to evaluate the safety/tolerability and characterize the pharmacokinetics of pevonedistat, alone or in combination with azacitidine, in this population, and determine the recommended phase 2/3 dose for pevonedistat plus azacitidine. Twenty-three adult patients with very high/high/intermediate-risk AML or MDS were enrolled in Japan, South Korea and Taiwan.

View Article and Find Full Text PDF
Article Synopsis
  • * This study evaluated a dasatinib-based 2-step induction treatment aiming for a higher event-free survival rate, with the first step using dasatinib and prednisolone to achieve complete remission and the second step using dasatinib with intensive chemotherapy for minimal residual disease negativity.
  • * Results showed that 78 patients achieved complete or incomplete remission after the first step, with 52.6% reaching minimal residual disease negativity in the second step, leading to a 3-year event
View Article and Find Full Text PDF
Article Synopsis
  • Gilteritinib, a FLT3 inhibitor, was recently approved in Japan as an effective treatment for FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), showing better overall survival than salvage chemotherapy in the ADMIRAL trial.
  • In the Japanese subgroup analysis, patients on gilteritinib had a median overall survival of 14.3 months compared to 9.6 months for those on salvage chemotherapy, with higher complete remission rates.
  • Gilteritinib also resulted in fewer adverse events, although some patients experienced significant issues like febrile neutropenia and anemia.
View Article and Find Full Text PDF
Article Synopsis
  • Mantle cell lymphoma (MCL) is a rare type of cancer that often becomes resistant to treatment, like the drug ibrutinib, so new treatment options are needed.
  • Researchers tested a new drug called OR-S1, which targets proteins called EZH1/2, and found that it worked better than ibrutinib in stopping tumor growth in mice with MCL.
  • The study showed that OR-S1 affects how MCL cells grow and change, and it works by targeting a protein called CDKN1C that helps control the cell cycle, making it a potential new treatment for tough-to-treat MCL.
View Article and Find Full Text PDF

Objectives: This study aimed to evaluate the outcomes of local radiotherapy (LRT) in patients with histologic transformation (HT) following rituximab-containing chemotherapy.

Methods: We retrospectively analysed 92 patients with biopsy-confirmed HT undergoing rituximab-containing chemotherapy at our institution between 2003 and 2015.

Results: Of the 36 patients with limited-stage disease at diagnosis of HT, 29 (78%) received LRT.

View Article and Find Full Text PDF

Although histologic analysis is the gold standard for diagnosing follicular lymphoma (FL) transformation, many patients are diagnosed with transformation by clinical factors as biopsy specimens often cannot be obtained. Despite the frequency of clinical diagnosis, no clinical assessment tool has yet been established for FL transformation in the rituximab era. We derived and validated a transformation scoring system (TSS) based on retrospective analyses of 126 patients with biopsy-proven FL and histologic transformation (HT) at two hospitals of the National Cancer Center of Japan.

View Article and Find Full Text PDF

Significant advancements have been achieved with regard to the outcomes of acute promyelocytic leukemia (APL) patients through the introduction of all-trans retinoic acid; however, early hemorrhagic death and differentiation syndrome remain the major causes of remission induction failure in patients with APL. To investigate early death, serious hemorrhage, and differentiation syndrome during remission induction therapy in terms of incidence, risk factors, influence on outcomes, and prophylactic effects of several new anticoagulants, the results of 344 patients enrolled in the Acute Promyelocytic Leukemia 204 study conducted by the Japan Adult Leukemia Study Group were analyzed. Early death was observed in 16 patients (4.

View Article and Find Full Text PDF

Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance of other important prognostic factors was evaluated with multivariate analyses.

Patients And Methods: Newly diagnosed acute promyelocytic leukemia (APL) patients were registered with the study.

View Article and Find Full Text PDF

Adult patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) have a poor prognosis. Blinatumomab is a bispecific T-cell engager (BiTE) immuno-oncology therapy with dual specificity for CD19 and CD3 that redirects patients' CD3-positive cytotoxic T cells to lyse malignant and normal B cells. We conducted an open-label, phase 1b/2 study to determine the safety, pharmacokinetics, efficacy and recommended dose of blinatumomab in Japanese adults with R/R B-precursor ALL.

View Article and Find Full Text PDF
Article Synopsis
  • * A study analyzed 54 newly diagnosed HL patients to compare the Lugano classification with the traditional Ann Arbor classification, finding an 85% agreement between the two.
  • * The research suggests that using FDG-PET/CT may reduce the need for routine bone marrow examinations in staging, given its low diagnostic yield in this context.
View Article and Find Full Text PDF

Extranodal NK/T cell lymphoma (NKTCL), nasal type (ENKL) that shows no apparent nasal involvement, is termed extranasal NKTCL or non-nasal NKTCL. In this study, we aimed to explore therapeutic approaches and outcomes in patients with extranasal NKTCL in current clinical practice. A data set of patients with newly diagnosed NKTCL who were diagnosed at 31 institutes in Japan between 2000 and 2013 was used for analysis.

View Article and Find Full Text PDF

Translocation (11;18)(q21;q21) is found in mucosa-associated lymphoid tissue (MALT) lymphoma, resulting in API2/MALT1 gene fusion. It is known that t(11;18)-positive MALT lymphoma shows a tendency to disseminate and be resistant to Helicobacter pylori eradication by antibiotics. However, the prognostic features including recurrence and histological transformation (HT) remain unknown.

View Article and Find Full Text PDF

Background: Waldenström macroglobulinemia (WM) is a rare, indolent B-cell lymphoma. Clinically, chromosome 6q deletion (6q del) including loss of the B lymphocyte-induced maturation protein 1 gene (BLIMP-1) is reported to be associated with poor prognosis. However, it remains unclear how the underlying biological mechanism contributes to the aggressiveness of WM with 6q del.

View Article and Find Full Text PDF

The treatment outcomes of adult acute lymphoblastic leukemia (ALL) have improved. Furthermore, the introduction of pediatric specific therapies has enhanced ALL treatment results in adolescents and young adult (AYAs). Age-related molecular signatures have also been identified, such as Philadelphia chromosome (Ph)-like ALL and DUX4/ERG gene-associated ALL.

View Article and Find Full Text PDF

Between April 2004 and December 2010, we conducted a prospective randomized controlled study comparing tamibarotene with all-trans retinoic acid (ATRA) in the maintenance therapy of newly diagnosed acute promyelocytic leukemia (APL), and here report the final results of this study with a median follow-up of 7.3 years. Of 344 eligible patients who had received ATRA and chemotherapy, 319 (93%) achieved complete remission (CR).

View Article and Find Full Text PDF